Archive · 8 Jun 2025
Mounjaro Sales Rise in India Amid Obesity Fight
Mounjaro, a drug by Eli Lilly for weight loss and diabetes, is doing well in India.
In May, sales of Mounjaro jumped 60%.
This is because more people in India need help managing their weight and diabetes.
The drug comes in two strengths.
The 5mg version sales doubled, which brought in a lot of revenue.
Newer patients are starting with a lower dose and then upgrading to the stronger one after four weeks.
Other companies are also working on similar drugs.
The generic versions are in development due to patent expirations, which may increase treatment options for the population.
Eli Lilly's Mounjaro sales in India increased by 60% in May.
The 5 mg version of Mounjaro sales more than doubled.
Total sales in May reached $1.5 million.
The increase in sales reflects the need for anti-obesity solutions in India.
Generic drugmakers are awaiting patent expirations to launch copycat treatments.
- Who
- Eli Lilly
- What
- Mounjaro sales increased 60%
- When
- May
- Where
- India
- Why
- Rising demand for obesity and diabetes treatments
Generics and Alternatives
Pharmaceutical Companies
Drug Availability
Generics and Alternatives
Generic drugmakers are awaiting the expiration of some patents to unleash copycat treatments.
Pharmaceutical Companies
Novo Nordisk is expected to launch Victoza in India, a daily dose alternative.
- Company
- Eli Lilly
- Drug
- Mounjaro (tirzepatide)
- Sales Increase (May)
- 60%
- Total Sales (May)
- $1.5 million
- 5 mg Sales (May)
- ₹7.5 crore
- Market
- India
- Drug Purpose
- Obesity and Type 2 Diabetes
Sources
Eli Lilly’s obesity drug sales spike 60% in India amid rising demand
Eli Lilly's Mounjaro hits Rs 24 crore sales in three months as adoption grows for diabetes and obesity in India
Lilly’s obesity drug sales rise 60% in India amid rising demand
